Purple Biotech CFO Resigns
Ticker: PPBT · Form: 6-K · Filed: Aug 5, 2024 · CIK: 1614744
Sentiment: neutral
Topics: management-change, cfo-resignation, biotech
TL;DR
Purple Biotech CFO Lior Fhima is out, heading for greener pastures.
AI Summary
On August 5, 2024, Purple Biotech Ltd. announced that its Chief Financial Officer, Lior Fhima, has resigned to pursue other opportunities. The company is based in Rehovot, Israel, and operates in the pharmaceutical preparations sector.
Why It Matters
The departure of a Chief Financial Officer can signal changes in financial strategy or stability, potentially impacting investor confidence and the company's stock performance.
Risk Assessment
Risk Level: medium — A CFO resignation can introduce uncertainty regarding financial management and future strategy, warranting closer investor scrutiny.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the 6-K report
- Lior Fhima (person) — Chief Financial Officer who resigned
- August 5, 2024 (date) — Date of the CFO's resignation notification
- Rehovot, Israel (location) — Company's principal executive offices
FAQ
Who is the outgoing Chief Financial Officer of Purple Biotech Ltd.?
Mr. Lior Fhima is the outgoing Chief Financial Officer of Purple Biotech Ltd.
When was the resignation of the CFO announced?
The resignation of the CFO was announced on August 5, 2024.
What is the reason cited for the CFO's resignation?
The CFO, Mr. Lior Fhima, resigned to pursue other opportunities.
What is Purple Biotech Ltd.'s primary business sector?
Purple Biotech Ltd. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where are Purple Biotech Ltd.'s principal executive offices located?
Purple Biotech Ltd.'s principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-08-05 16:01:02
Filing Documents
- ea0210615-6k_purple.htm (6-K) — 15KB
- 0001213900-24-065181.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. August 5, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2